|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 273.50 EUR | +3.83% |
|
+4.71% | +16.38% |
| 06-05 | Glenmark Pharmaceuticals Launches Generic Seizure Drug in US | MT |
| 06-04 | UCB and Biogen Inc. Demonstrate Clinical Profile of Dapirolizumab Pegol in Systemic Lupus Erythematosus At EULAR 2026 | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- UCB Stock
- UNC Stock
- Consensus UCB
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
